Binghua Li , Qiang Wang , Weiwei Hu , Huan Li , Peng Yan , Yajuan Cao , Decai Yu
{"title":"关于 \"接受阿特珠单抗加贝伐单抗治疗后病情持久部分应答或持久稳定的肝细胞癌患者的临床疗效和组织学检查结果 \"的评论","authors":"Binghua Li , Qiang Wang , Weiwei Hu , Huan Li , Peng Yan , Yajuan Cao , Decai Yu","doi":"10.1016/j.iliver.2024.100130","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100130"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”\",\"authors\":\"Binghua Li , Qiang Wang , Weiwei Hu , Huan Li , Peng Yan , Yajuan Cao , Decai Yu\",\"doi\":\"10.1016/j.iliver.2024.100130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":100657,\"journal\":{\"name\":\"iLIVER\",\"volume\":\"3 4\",\"pages\":\"Article 100130\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"iLIVER\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772947824000550\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"iLIVER","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772947824000550","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”